Samuel Kintz Sells 12,000 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CEO Samuel Kintz sold 12,000 shares of the firm’s stock in a transaction dated Tuesday, June 25th. The shares were sold at an average price of $21.66, for a total value of $259,920.00. Following the sale, the chief executive officer now directly owns 1,075,525 shares in the company, valued at approximately $23,295,871.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Samuel Kintz also recently made the following trade(s):

• On Tuesday, May 28th, Samuel Kintz sold 12,000 shares of Enliven Therapeutics stock. The stock was sold at an average price of $23.18, for a total value of $278,160.00.
• On Thursday, April 25th, Samuel Kintz sold 12,000 shares of Enliven Therapeutics stock. The stock was sold at an average price of $16.89, for a total value of $202,680.00.
• On Thursday, April 11th, Samuel Kintz sold 47,709 shares of Enliven Therapeutics stock. The stock was sold at an average price of $25.04, for a total value of $1,194,633.36.

Enliven Therapeutics Stock Down 0.3 %

Enliven Therapeutics stock opened at $23.37 on Friday. Enliven Therapeutics, Inc. has a 52 week low of $9.80 and a 52 week high of $26.00. The company has a market capitalization of $1.10 billion, a price-to-earnings ratio of -12.11 and a beta of 1.11. The stock has a 50-day moving average price of $21.66 and a 200 day moving average price of $17.75.

Enliven Therapeutics (NASDAQ:ELVN) last released its earnings results on Tuesday, May 14th. The company reported ($0.54) EPS for the quarter, topping analysts’ consensus estimates of ($0.58) by $0.04. Research analysts anticipate that Enliven Therapeutics, Inc. will post -2.26 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have weighed in on ELVN shares. Baird R W raised Enliven Therapeutics to a “strong-buy” rating in a report on Tuesday, June 11th. Mizuho assumed coverage on Enliven Therapeutics in a report on Tuesday, April 9th. They set a “buy” rating and a $34.00 target price for the company. Finally, Robert W. Baird assumed coverage on Enliven Therapeutics in a report on Tuesday, June 11th. They set an “outperform” rating and a $32.00 target price for the company.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of ELVN. AJOVista LLC purchased a new position in Enliven Therapeutics during the fourth quarter valued at approximately $28,000. China Universal Asset Management Co. Ltd. purchased a new position in Enliven Therapeutics during the fourth quarter valued at approximately $66,000. Exchange Traded Concepts LLC raised its position in Enliven Therapeutics by 34.0% during the fourth quarter. Exchange Traded Concepts LLC now owns 8,708 shares of the company’s stock valued at $121,000 after acquiring an additional 2,208 shares in the last quarter. EntryPoint Capital LLC purchased a new position in Enliven Therapeutics during the first quarter valued at approximately $167,000. Finally, Mirae Asset Global Investments Co. Ltd. raised its position in Enliven Therapeutics by 9.1% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 12,305 shares of the company’s stock valued at $170,000 after acquiring an additional 1,029 shares in the last quarter. 95.08% of the stock is currently owned by hedge funds and other institutional investors.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.